Figure 1.
Conditioning regimen and engraftment. (A) Study schema. Peri-HCT ruxolitinib administration was from day −3 pre-HCT to day +30 post-HCT. Neutrophil (B) and platelet (C) engraftment post-HCT. aGVHD, acute GVHD; PO, orally; QD, once daily.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.